FDA Says It Can Approve Follow-On Biologics

Washington Drug Letter
KEYWORDS DrugApprovals / FDA
A A
The FDA released a white paper saying it has the ability to approve follow-on biologics without extensive clinical trials, although some trials would be necessary for the follow-ons to replace original products.

To View This Article:

Login